Cargando…

Accuracy of breast MRI in evaluating nodal status after neoadjuvant therapy in invasive lobular carcinoma

Neoadjuvant therapy in breast cancer can downstage axillary lymph nodes and reduce extent of axillary surgery. As such, accurate determination of nodal status after neoadjuvant therapy and before surgery impacts surgical management. There are scarce data on the diagnostic accuracy of breast magnetic...

Descripción completa

Detalles Bibliográficos
Autores principales:	Abel, Mary Kathryn, Greenwood, Heather, Kelil, Tatiana, Guo, Ruby, Brabham, Case, Hylton, Nola, Wong, Jasmine, Alvarado, Michael, Ewing, Cheryl, Esserman, Laura J., Boughey, Judy C., Mukhtar, Rita A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7935955/ https://www.ncbi.nlm.nih.gov/pubmed/33674614 http://dx.doi.org/10.1038/s41523-021-00233-9

Ejemplares similares

4314 The Impact of Axillary Surgery on Recurrence-Free Survival in Invasive Lobular Carcinoma (ILC) of the Breast
por: Abel, Mary Kathryn Reed, et al.
Publicado: (2020)

Success rates of re-excision after positive margins for invasive lobular carcinoma of the breast
por: Piper, Merisa L., et al.
Publicado: (2019)

Predictors of Early Versus Late Recurrence in Invasive Lobular Carcinoma of the Breast: Impact of Local and Systemic Therapy
por: Rothschild, Harriet T., et al.
Publicado: (2023)

Changes in Management Strategy and Impact of Neoadjuvant Therapy on Extent of Surgery in Invasive Lobular Carcinoma of the Breast: Analysis of the National Cancer Database (NCDB)
por: Mukhtar, Rita A., et al.
Publicado: (2021)

Area Deprivation Index in Patients with Invasive Lobular Carcinoma of the Breast: Associations with Tumor Characteristics and Outcomes
por: Kaur, Mandeep, et al.
Publicado: (2023)

Expanding Candidacy for Nipple-sparing Mastectomy in Women with Large or Ptotic Breasts: Staged Reconstruction Outcomes
por: Barnes, Laura L., et al.
Publicado: (2023)

Identifying Good Candidates for Active Surveillance of Ductal Carcinoma In Situ: Insights from a Large Neoadjuvant Endocrine Therapy Cohort
por: Glencer, Alexa C., et al.
Publicado: (2022)

Current Landscape of Breast Cancer Imaging and Potential Quantitative Imaging Markers of Response in ER-Positive Breast Cancers Treated with Neoadjuvant Therapy
por: Jones, Ella F., et al.
Publicado: (2020)

Clinically Meaningful Tumor Reduction Rates Vary by Prechemotherapy MRI Phenotype and Tumor Subtype in the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657)
por: Mukhtar, Rita A., et al.
Publicado: (2013)

Effect of Imaging Parameter Thresholds on MRI Prediction of Neoadjuvant Chemotherapy Response in Breast Cancer Subtypes
por: Lo, Wei-Ching, et al.
Publicado: (2016)

Decreased enrollment in breast cancer trials by histologic subtype: does invasive lobular carcinoma resist RECIST?
por: Abel, Mary Kathryn, et al.
Publicado: (2021)

FGFR-1 amplification in metastatic lymph-nodal and haematogenous lobular breast carcinoma
por: Brunello, Eleonora, et al.
Publicado: (2012)

The incidence of discordant clinical and genomic risk in patients with invasive lobular or ductal carcinoma of the breast: a National Cancer Database Study
por: Abel, Mary Kathryn, et al.
Publicado: (2021)

The impact of histologic subtype on primary site surgery in the management of metastatic lobular versus ductal breast cancer: a population based study from the National Cancer Database
por: Rothschild, Harriet T, et al.
Publicado: (2023)

Successful Breast Conservation After Neoadjuvant Chemotherapy in Lobular Breast Cancer: The Role of Menopausal Status in Response to Treatment
por: Ramalingam, Kirithiga, et al.
Publicado: (2023)

Comparison of Syndecan-1 Immunohistochemical Expression in Lobular and Ductal Breast Carcinoma with Nodal Metastases
por: Miše, Ivana, et al.
Publicado: (2018)

ASO Author Reflections: Right Sizing Axillary Surgery in Patients treated with Neoadjuvant Endocrine Therapy
por: Hieken, Tina J., et al.
Publicado: (2021)

Comparison of Segmentation Methods in Assessing Background Parenchymal Enhancement as a Biomarker for Response to Neoadjuvant Therapy
por: Nguyen, Alex Anh-Tu, et al.
Publicado: (2020)

Effect of MR Imaging Contrast Thresholds on Prediction of Neoadjuvant Chemotherapy Response in Breast Cancer Subtypes: A Subgroup Analysis of the ACRIN 6657/I-SPY 1 TRIAL
por: Li, Wen, et al.
Publicado: (2016)

Tumor Sphericity Predicts Response in Neoadjuvant Chemotherapy for Invasive Breast Cancer
por: Li, Wen, et al.
Publicado: (2020)

Impact of MRI Protocol Adherence on Prediction of Pathological Complete Response in the I-SPY 2 Neoadjuvant Breast Cancer Trial
por: Onishi, Natsuko, et al.
Publicado: (2020)

Modulation of the immune microenvironment of high-risk ductal carcinoma in situ by intralesional pembrolizumab injection
por: Glencer, Alexa C., et al.
Publicado: (2021)

Features of MRI stromal enhancement with neoadjuvant chemotherapy: a subgroup analysis of the ACRIN 6657/I-SPY TRIAL
por: Olshen, Adam, et al.
Publicado: (2017)

Radiomic tumor phenotypes augment molecular profiling in predicting recurrence free survival after breast neoadjuvant chemotherapy
por: Chitalia, Rhea, et al.
Publicado: (2023)

ASO Author Reflections: Discordant Clinical and Molecular Risk in Invasive Lobular Carcinoma of the Breast: The 21-Gene Recurrence Score in the National Cancer Database by Histologic Subtype
por: Abel, Mary Kathryn, et al.
Publicado: (2022)

Surgical Management of Axilla Following Neoadjuvant Endocrine Therapy
por: Murphy, Brenna M., et al.
Publicado: (2021)

Obesity and menopausal status impact the features and molecular phenotype of invasive lobular breast cancer
por: Rothschild, Harriet T., et al.
Publicado: (2021)

Neoadjuvant chemotherapy in locally advanced invasive lobular carcinoma: A limited institutional experience
por: Gogia, Ajay, et al.
Publicado: (2018)

Clinical Outcomes and Prognostic Factors In Triple-Negative Invasive Lobular Carcinoma of the Breast
por: Joshi, Utsav, et al.
Publicado: (2023)

Diffusion Tensor Imaging for Assessment of Response to Neoadjuvant Chemotherapy in Patients With Breast Cancer
por: Wilmes, Lisa J., et al.
Publicado: (2016)

ASO Visual Abstract: Surgical Management of Axilla Following Neoadjuvant Endocrine Therapy
por: Murphy, Brenna M., et al.
Publicado: (2021)

Circulating tumor DNA and magnetic resonance imaging to predict neoadjuvant chemotherapy response and recurrence risk
por: Magbanua, Mark Jesus M., et al.
Publicado: (2021)

Clinical benefit from neoadjuvant chemotherapy in oestrogen receptor-positive invasive ductal and lobular carcinomas
por: Delpech, Y, et al.
Publicado: (2013)

Differences in Response and Surgical Management with Neoadjuvant Chemotherapy in Invasive Lobular Versus Ductal Breast Cancer
por: Truin, W., et al.
Publicado: (2015)

Survival Outcomes in Invasive Lobular Carcinoma Compared to Oestrogen Receptor-Positive Invasive Ductal Carcinoma
por: Timbres, Jasmine, et al.
Publicado: (2021)

Neoadjuvant T-DM1/pertuzumab and paclitaxel/trastuzumab/pertuzumab for HER2(+) breast cancer in the adaptively randomized I-SPY2 trial
por: Clark, Amy S., et al.
Publicado: (2021)

Diffusion-Weighted MRI for Predicting Pathologic Complete Response in Neoadjuvant Immunotherapy
por: Li, Wen, et al.
Publicado: (2022)

The 21-Gene Recurrence Score in Clinically High-Risk Lobular and Ductal Breast Cancer: A National Cancer Database Study
por: Abel, Mary Kathryn, et al.
Publicado: (2022)

Change in Main Histological Type of Invasive Breast Cancer From Ductal to Lobular Carcinoma by Neoadjuvant Chemotherapy
por: Okubo, Takako, et al.
Publicado: (2023)

MRI Enhancement in Stromal Tissue Surrounding Breast Tumors: Association with Recurrence Free Survival following Neoadjuvant Chemotherapy
por: Jones, Ella F., et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_maldikg7o8ikc50736ovkk7d4o